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Abstract:  Chemotherapy  including  high
radiotherapy, is standard treatment for primary central nervous system lymphoma (PCNSL). 
It remains controversial whether addition of other drugs will add to therapeutic efficacy. We 
report  here  on  41  patients  with  PCNSL  treated  using  a  combined  treatment  modality, 
including HD-MTX (3.5 g/m
2 for 2 cycles) prior to whole brain radiotherapy (WBRT). In 22 
patients, the chemotherapy was intensified by adding high
AraC)  (2g/m
2 for  4  doses  for  2  cycles).  Complete  remission  at  the  end  of  the  combined 
treatment was obtained in 23 of 34 assessable patients (67%), and the predicted 5
and disease-free survival rates were 24% and 46%, respectively, without 
treatment groups. The addition of HD
(77%) patients, resulting in 3 toxic deaths. Our study indicates that addition of HD
not improve clinical outcome in PCNSL, while it increa
toxic therapies are warranted.
Introduction: Non-Hodgkin 
exclusively localized in the brain are usually B
lymphomas of the diffuse large B cell type and are 
characterized  by  an  aggressive  clinical  course
Surgical  procedures  are  essential  for  histological 
diagnosis, but resection has no benefit
but is often complicated by neurological sequelae. 
Irradiation in the form of whole brain radiotherapy 
(WBRT)  can  often  induce  remissions,  but  the 
majority  of  patients  relapse,  and  median  overall 
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Chemotherapy  including  high-dose  methotrexate  (HD-MTX),  with  or  without 
radiotherapy, is standard treatment for primary central nervous system lymphoma (PCNSL). 
It remains controversial whether addition of other drugs will add to therapeutic efficacy. We 
eport  here  on  41  patients  with  PCNSL  treated  using  a  combined  treatment  modality, 
for 2 cycles) prior to whole brain radiotherapy (WBRT). In 22 
patients, the chemotherapy was intensified by adding high-dose cytosine arabinoside (
for  4  doses  for  2  cycles).  Complete  remission  at  the  end  of  the  combined 
treatment was obtained in 23 of 34 assessable patients (67%), and the predicted 5
free survival rates were 24% and 46%, respectively, without 
treatment groups. The addition of HD-AraC was complicated by severe infections in 17/22 
(77%) patients, resulting in 3 toxic deaths. Our study indicates that addition of HD
not improve clinical outcome in PCNSL, while it increases toxicity. More targeted and less 
Hodgkin  lymphomas 
exclusively localized in the brain are usually B-cell 
lymphomas of the diffuse large B cell type and are 
characterized  by  an  aggressive  clinical  course
1,2. 
Surgical  procedures  are  essential  for  histological 
diagnosis, but resection has no benefit for survival, 
but is often complicated by neurological sequelae. 
Irradiation in the form of whole brain radiotherapy 
(WBRT)  can  often  induce  remissions,  but  the 
majority  of  patients  relapse,  and  median  overall 
survival is only 11 to 14 months
combination chemotherapy such as CHOP, which is 
standard treatment for systemic NHL, but does not 
contain drugs which cross the blood brain barrier, to 
WBRT  did  not  improve  the  outcome  of  patients 
with  primary CNS lymphomas (PCNSL)
the  combination  of  methotrexate  administered  at 
high doses prior to WBRT has improved response 
rates  and  survival  in  PCNSL
consensus  that  HD-MTX  is  the  single  most
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MTX),  with  or  without 
radiotherapy, is standard treatment for primary central nervous system lymphoma (PCNSL). 
It remains controversial whether addition of other drugs will add to therapeutic efficacy. We 
eport  here  on  41  patients  with  PCNSL  treated  using  a  combined  treatment  modality, 
for 2 cycles) prior to whole brain radiotherapy (WBRT). In 22 
dose cytosine arabinoside (HD-
for  4  doses  for  2  cycles).  Complete  remission  at  the  end  of  the  combined 
treatment was obtained in 23 of 34 assessable patients (67%), and the predicted 5-year overall 
free survival rates were 24% and 46%, respectively, without differences between 
AraC was complicated by severe infections in 17/22 
(77%) patients, resulting in 3 toxic deaths. Our study indicates that addition of HD-AraC may 
ses toxicity. More targeted and less 
survival is only 11 to 14 months
3. The addition of 
combination chemotherapy such as CHOP, which is 
standard treatment for systemic NHL, but does not 
contain drugs which cross the blood brain barrier, to 
WBRT  did  not  improve  the  outcome  of  patients 
with  primary CNS lymphomas (PCNSL)
1-3. Only 
ination  of  methotrexate  administered  at 
high doses prior to WBRT has improved response 
rates  and  survival  in  PCNSL
4,5.  There  is  a  broad 
MTX  is  the  single  mostMedit J Hemat Infect Dis 2009, 1(2): Open Journal System
Table 1.  Patient characteristics
total 
(n=41)
HD-MTX
(n=19)
HD-MTX/AraC
(n=22)
Age
Median, years 
Range, years
> 60 years (%)
59 
31-78
44
64
31-78
58
56
40-72
41
Gender
Female
Male
21
20
8
11
13
9
Surgical procedure
Stereotactic biopsy
Tumour resection
Not performed
25
12
4
14
4
1
11
8
3
Lesions 
Single
Multiple
15
26
8
11
7
15
IELSG score:
0-1
2-3
4-5
n.a.
6
21
8
6
2
12
2
3
4
9
6
3
CSF cytology
Negative
Positive 
Not performed
24
  6
11
11
3
5
13
3
6
HD-MTX, high-dose methotrexate; AraC, cytarabine; IELSG, international extra-nodal lymphoma study group; CSF, cerebrospinal 
fluid. The Fisher’s exact test was used to compare the frequencies of patient’s characteristics according to treatment groups. No 
significant differences were found. 
important  cytotoxic  drug  in  the  treatment  of 
PCNSL
6. 
The  combined  modality  of  chemotherapy 
including MTX at high doses followed by WBRT is 
now  considered  standard  treatment.  Despite  the 
progress reported in clinical studies prognosis still 
remains  poor.  The  International  Extranodal 
Lymphoma  study  group  (IELSG)  has  recently 
defined  a  prognostic  score  consisting  of  five 
parameters to predict prognosis, while the Memorial 
Sloan-Kettering  group  identified  only  age  and 
performance  status  as  the  only  variables  in 
multivariate  analysis
7,8.  Older  age  and  poor 
performance  status  are  often  limiting  factors  to 
perform aggressive therapies, and these patients are 
often  excluded  from  clinical  trials.  This  may 
contribute to the fact that progress in the treatment 
of PCNSL suggested by clinical trials do not result 
in changes in the outcome, observed over time in 
cancer registries or single centers
9-11.   
Improvement  of  treatment  results  are  urgently 
needed, and one strategy is to add cytotoxic agents 
to increase efficacy of chemotherapy. It is not yet 
known  whether  the  addition  of  other  cytotoxic 
agents  adds  to  the  efficacy  of  HD-MTX.  Some 
alkylating agents as BCNU, thiotepa, busulfane, and 
procarbazine cross the blood-brain barrier at normal 
doses,  while  cytosine  arabinoside  (AraC)  crosses 
the  barrier  only  at  high-doses.  There  is  some 
evidence  from  retrospective  analyses  that  HD-
AraC added to HD-MTX-based chemotherapy may 
improve  outcome
4,5.  We  report  here  on  a  single 
center  experience  in  41  patients  with  PCNSL 
treated  with  a  combined  modality  including  HD-
MTX prior to WBRT, with addition of HD-AraC in 
22 of them. 
Patients and Methods
Patients:  Forty-one  consecutive  HIV-negative 
patients  diagnosed  with  PCNSL  between  March 
1995 and May 2004 were included into this study. 
The median age  was 59 years (range 32-78), 21 
patients were females and 20 males. Diagnosis of 
PCNSL was made by histological examination of a 
stereotactic biopsy in 25 patients and by partial or 
total resection in 12 patients. In 4 patients, histology 
was not attempted due to poor performance status 
or to the high risks associated with the particular 
localization  of  the  cerebral  lesion,  in  the  deep 
structures  of  the  brain.  These  patients  had 
radiological  features  compatible  with  lymphoma. 
Moreover, a clonal B-cell population was detected  
in CSF in 2 patients, while in further 2 patients the 
diagnosis  was  suggested  by  the  marked  initial 
improvement  of  the  disease  by  corticosteroids. 
Initial evaluation included radiological examination 
through magnetic resonance imaging (MRI) and/or 
computed tomography (CT) scan of the brain and Medit J Hemat Infect Dis 2009, 1(2): Open Journal System
Table 2.  Feasibility, Toxicity and Outcome of HD-MTX-based chemotherapy in PCNSL
HD-MTX
(n=19)
HD-MTX/HD-AraC 
(sequential)
(n=13)
HD-MTX/HD-AraC 
(combined)
(n=9)
Renal toxicity             (grade 3/4) 0/0  (0%) 0/0 (0%) 1/0 (11%)
Liver toxicity              (grade 3/4)  2/1 (16%) 1/0 (8%) 1/0 (11%)
Anemia                       (grade 3/4)  2/1 (16%) 2/0 (15%) 3/1 (44%)
Thrombocytopenia    (grade 3/4) 2/6 (42 %) 0/5 (38%) 0/5 (56%)
Neutropenia               (grade 3/4)  1/7 (42%) 0/9 (69%) 0/8 (89%)
Infections                    (grade 3/4) 3/3 (32%) 5/3 (62%) 5/2 (78%)
Pts who completed chemotherapy as 
planned
15 (79%)   9 (69%) 4 (44%)
Reasons for change of therapy Renal tox. 2
Liver tox. 2
Renal tox. 1
Infections 2
Progression 1
Renal tox. 1
Infections 4
Toxic Death  3 (16%) 1 (8%) 3 (33%)
Complete Remission  12/16 (75%) 7/12 (58 %) 4/6 (67%)
lumbar  puncture  with  CSF  examination.  Fifteen  
patients presented a single cerebral lesion and 26 
patients  multiple  lesions.  CT  scans  of  chest, 
abdomen  and  pelvis  and  bone  marrow  histology 
were performed to exclude systemic localizations. 
Moreover, data about performance status (according 
to  W.H.O.  classification)  and  clinical  symptoms 
were  collected,  to  calculate  prognostic  score 
according  to  IELSG.  Patients  characteristics  are 
summarized in Table 1. 
Treatment: For all patients a combined regimen of 
2  cycles  of  high-dose  methotrexate  (HD-MTX)-
based  chemotherapy  followed  by  whole  brain 
radiotherapy was planned: 19 patient received HD-
MTX only, at the dose of 3.5 g/m
2 for two courses 
on days 1 and 22, 13 patients treated between 1998 
and 2002 received a sequential therapy of HD-MTX 
(same schedule as above) followed by HD-AraC at 
the dose of 2 g/m
2 every 12 hours for 2 days and for 
2 courses (on days 43 and 64), 9 patients younger 
than  61  years  treated  between  2000  and  2002 
received a combined regimen of HD-MTX 3.5 g/m
2
the first day and HD-AraC 2 g/m
2 every 12 hours on 
days 2 and 3. Systemic HD-MTX was administered 
as a 6-hour infusion under vigorous hydration and 
urine alkalinization and was followed by leucovorin 
rescue. HD-AraC was given as a 3 hour infusion. 
The  6  patients  with  a  positive  CSF  cytology 
received  intrathecal  chemotherapy  in  addition  to 
systemic i.v. chemotherapy. In 36 patients, whole 
brain radiotherapy (40 Gy) with a boost of 20 Gy to 
the involved area or residual lesions completed the 
treatment.  Prophylaxis  with  subcutaneous  low 
molecular weight heparin was given from 1999 on. 
Statistical  analysis:  The  Fisher’s  exact  test  was 
used  to  compare  the  frequencies  of  patient’s 
characteristics according to different groups.  The 
response  to  treatment  was  evaluated  after 
chemotherapy  and  at  the  end  of  the  treatment 
(chemo- and  radiotherapy).  Complete  Remission 
(CR)  was  defined  as  the  disappearance  of  all 
enhancing lesions 
12.  Partial Remission (PR) was 
defined as the decrease of more than 50% of the 
size  of  lesions  with  contrast  enhancement,  while 
progressive  disease  (PD)  was  defined  by  the 
increase  of  existing  lesions  or  appearance  of  any 
new lesion. 
Overall Survival (OS) was calculated from the 
diagnosis to death for any causes or last follow up 
Disease Free Survival (DFS) was calculated from 
the  date  documenting  a  CR  at  the  end  of  the 
combined treatment until date of relapse. Survival 
curves were calculated using the method of Kaplan 
and Meier. The log-rank test was used to compare 
OS and DFS according to different patient groups. 
Differences  were  considered  significant  only  for 
p<0.05. Statistical analysis was performed using the 
Stata 7 program. 
Results
Treatment response and disease control: Response 
to chemotherapy could not be assessed in 4 patients 
who died during chemotherapy due to toxicity. Of 
37 assessable patients, 11 patients (30%) achieved 
complete  response,  8  patients  (22%)  partial 
response  and 18  patients (49%)  showed stable or 
progressive disease. In particular, CR was observed 
in 4/18 cases (22%) in the group of patients who Medit J Hemat Infect Dis 2009, 1(2): Open Journal System
Table 3.  Causes of Death
received HD-MTX alone and in 7/19 cases (37%) in 
the group treated with HD-MTX  and HD-AraC.
Response at the end of combined treatment was 
assessable  in  34  patients, since  3  pts  died  during 
radiation therapy due to toxicity. Twenty-three  of 
these  34  patients  (67%)  achieved  complete 
remission,  without  differences  between  the 
treatment  groups  [12/16 (75%)  in  the  HD-MTX 
alone group and 11/18 (61%) in the HD-MTX/HD-
AraC group, respectively] (Table 2).  In conclusion, 
in the HD-MTX group 12 of the initial 19 patients 
(63%)  were  alive  in  CR,  while  in  the  HD-
MTX/HD-AraC group 11 of the initial 22 patients
(50%) were alive in CR.
Outcome: Thirty-one of the 41 patients deceased, 
16  patients  due  to  progressive  disease,  and  15 
patients for other reasons, mainly treatment-related 
complications  (11  patients)  (Table  3).  Infections 
and thromboembolic complications were the major 
causes of death during the treatment period, while 
neurologic  sequelae  of  the  disease/treatment  were 
the major causes of death in remission after the end 
of  treatment.  Two  patients  died  due to  secondary 
malignancies (1 colon cancer, 1 diffuse metastatic 
cancer). 
The  predicted  5-year  disease-free  survival  rate 
was  46%  with  no  differences  between  treatment 
groups (p=0.5) (Figure 1). Median overall survival 
was  22  months,  and  the  predicted  5-year  overall 
survival  was  24%  (95%  C.I.,11-39)  without 
differences  between  treatment  groups  (Figure  2).  
In  35  patients,  sufficient  data  were  available  to 
calculate the IELSG prognostic score. 
Figure 1. The addition of high-dose cytarabine (AraC) to high-dose methotrexate (MTX) did not improve disease-free survival 
(DFS). Kaplan-Meier plots for DFS of 23 patients with PCNSL achieving complete remission after combined modality treatment 
according to type of chemotherapy (MTX alone, n=12;  MTX/AraC, n=11) are shown. P refers to log-rank test.
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Figure 2. The addition of high-dose cytarabine (AraC) to high-dose methotrexate (MTX) did not improve overall survival. Kaplan-
Meier plots for overall survival of 41 patients with PCNSL according to type of chemotherapy (MTX alone, n=19;  MTX/AraC, 
n=22) are shown. P refers to log-rank test.
We  observed  a  trend  for  differences  in  overall 
survival  according  to  the  IELSG  score  (p=0.08) 
(Figure 3). 
Toxicity:  The  HD-MTX-based  chemotherapy  was 
complicated by liver and renal toxicity leading to 
subsequent  modification  of  treatment  with  early 
administration  of  radiotherapy  in  4  pts  receiving 
HD-MTX alone (21%) and in 2 pts (10%) of the 
group receiving HD-MTX/HD-AraC. Haematologic 
toxicity  was  frequent  and  more  pronounced  in 
patients  receiving  additional  HD-AraC (Table  2). 
Grade 4 neutropenia was observed in 7/19 (37%)
patients  receiving  HD-MTX  alone,  and  in  17/22 
(77%) patients receiving additional HD-AraC. As a 
consequence, severe infections particularly occurred 
in  patients  receiving  HD-AraC  and  increased  the
Figure 3. The IELSG prognostic score predicts overall survival in PCNSL. Kaplan-Meier plots for overall survival of 35 patients 
with PCNSL according to the IELSG score (score 0-1, n=6;  score 2-3, n=21, score 4-5, n=8) are shown. P refers to log-rank test. 
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toxic death rate which was particular high among 
patients  receiving  the  combination  of  HD-
MTX/AraC (3/9, 33%), while the toxic death rate in 
patients  treated  with  HD-MTX    with  or  without 
sequential HD-AraC was 8% (1/8) and  16% (3/19)  
respectively. All 7 toxic death occurred inpatients 
with an initially reduced performance status (PS >
2). Treatment could be completed as programmed 
in 15/19 patients (79%) in the group receiving HD-
MTX as the only cytotoxic agent, in 9 of 13 patients 
(69%) in the sequential HD-MTX/HD-AraC and in 
only  4/9  (44%)  patients  in  the  combined  HD-
MTX/HD-AraC  group. Thromboembolic 
complications were frequent and occurred in 9 of 41 
patients  (22%):  deep  venous  thrombosis  and/or 
pulmonary embolism were observed at the time of 
diagnosis  in  3  patients,  during  chemotherapy  and 
radiotherapy  in  4  and  2  patients,  respectively. 
Thrombembolic events were fatal. in 3 patients.
Discussion:  Treatment  results  in  PCNSL  are  still 
unsatisfactory due to scarce disease control and to 
therapy-related  toxicity.  Although  prospective 
clinical trials indicate a progressive improvement in 
prognosis for  PCNSL in  recent years, analysis of 
cancer  registries  or  single  centers  experiences  do 
not suggest a significant progress in the treatment 
results over time
9-11. Combined modality with  HD-
MTX and WBRT is considered standard, and it is 
unclear  whether  the  addition  of  other  cytotoxic 
drugs may improve disease control. 
We  report  a  series  of  41  patients  sequentially 
treated in a single center, at a median follow-up of  
6  years.  Focus  of  our  analysis  was  whether  the 
addition  of  HD-AraC  to  a  combined  approach 
consisting  of  HD-MTX  and  WBRT  improves  on 
treatment results. 
Retrospective, non-randomized studies indicated 
that the addition of HD-AraC may improve overall 
survival. In a retrospective analysis including 226 
patients  with  PCNSL,  Blay  et  al found  that 
treatment  with  chemotherapy  versus  radiotherapy 
only,  and  treatment  including  HD-MTX  or  HD-
AraC  were  prognostic  factors  in  the  univariate 
analysis
4.  However,  in  the  multivariate  analysis, 
HD-MTX  remained  the  only  independent 
prognostic factor. The retrospective analysis of 160 
patients  treated  with  HD-MTX-based  primary 
chemotherapy by Ferreri et al showed that patients 
treated  with  combinations  of  HD-MTX  and  HD-
AraC    had  a  better  overall  survival  than  patients 
treated  with  HD-MTX  only
5.  Therapy  with  HD-
MTX  without subsequent  radiotherapy  is 
characterized by a high proportion of early relapses 
after  a  median  of  12-14  months
13,14.  Pels  et  al
reported  on  results  in  65  patients  with  PCNSL 
treated  with  alternating  cycles  of  chemotherapy 
including  either  HD-MTX  or  HD-AraC  and 
deferred  radiotherapy
15.  The  median  overall 
survival  was  50  months,  and  results  were 
particularly encouraging in patients younger than 60 
years.  Six  (9%)  of  the  patients  died  because  of 
treatment-related  complications,  and  systemic 
toxicity was mainly haematologic. In our series, the 
addition  of  HD-AraC  combined  to  HD-MTX 
increased the risk of infections, resulting in changes 
of the treatment program in 6 of 22 patients and in 
toxic death in 3 of 22 patients.  In addition, HD-
AraC did not increase the complete remission rate, 
and  did  not  improve  disease-free  and  overall 
survival. In conclusion, in our hands, the addition of  
HD-AraC  into  a  combined  HD-MTX/WBRT 
program  increased  the  toxicity  of  the  treatment 
without improving disease control. As only 4 of the 
9  patients  in  the  combined  treatment  group 
completed therapy as planned, this might indicate 
that  this  therapy  is  too  toxic  for  the  majority  of 
patients, who are often severely debilitated by the 
disease.  A  sequential  approach  appears  more 
feasible. Given  however  the  limited  number  of 
patients  in  our  study,  it  is  too  early  to  draw  a 
definite conclusion on the benefit or failure of HD-
AraC addition.  Prospective clinical studies as the 
ongoing trial of the IELSG are needed to definitely 
evaluate  the  role  of  HD-AraC  in  a  combined 
modality  approach.  Better  selection  criteria  and 
better supportive care might help to improve results. 
As  the  majority  of  patients  with  PCNSL  are 
debilitated  by  the  neurologic  sequelae  of  the 
disease,  they  are  at  particular  risk  for  infectious 
complications  following  myelosuppressive 
therapies.  Our  case  series  also  underlines  that 
patients    with  PCNSL  are  at  risk  for  fatal 
thromboembolic  events  during  treatment  and 
neurotoxicity  after  the  end  of  treatment,  reducing 
overall survival in remission. The increased risk for 
thromboembolic events in patients with PCNSL is 
now recognized, while the underlying mechanisms 
remain unclear
16. As thromboembolic events can be 
present already at diagnosis, they do not appear to 
be  treatment-induced  or  to  be  dependent  on  the 
performance status of the patient or to correlate to 
immobilization.  Analysis of  hereditary  factors  for 
thrombophilia  did  not  help  to  identify patients  at 
risk  for  thromboembolism.  We  now  perform 
prophylaxis  in  all  patients  with  low  molecular 
weight heparin. It is unclear whether this will have 
an  impact  on  the  incidence  of  thromboembolic 
events as these often are present at diagnosis. In our 
series,  4  of  9  thromboembolic  events  were 
registered  at  diagnosis  before  starting  cytotoxic Medit J Hemat Infect Dis 2009, 1(2): Open Journal System
therapy.  In  addition,  risks  of  anticoagulation  in 
patients with brain lesions have to be borne in mind. 
Neurotoxicity  was  the  reason  for  death  in  4 
patients,  all  older  than  60  years.  Neurotoxicity  is 
attributed  to  WBRT,  and  patients  aged  over  60 
years  are  at  increased  risk
17.  The  omission  of 
WBRT form treatment programs however reduces 
the  disease control.  Less toxic  and  more  targeted 
therapies are needed to improve outcome of patients 
with  PCNSL  in  the  future.  Examples  for  such  
attempts are the addition of monoclonal antibodies, 
braking/interrupting the brain barrier with mannitol, 
or  intensified  therapies  supported  with  peripheral 
blood stem cell support
18.
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